SCHEMBL6411628

SCHEMBL6411628

Cc1cn2ccc(C(=O)N[C@@H]3CC4CCN(C4)C3)cc2n1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 10/20 0.53
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HDAC1 Q13547 1/20 0.39
HRH3 Q9Y5N1 1/20 0.37
RIPK2 O43353 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417094 1.00 CHRNA7 (0.53) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6417099 1.00 CHRNA7 (0.53) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6413984 0.88 CHRNA7 (0.58) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6410974 0.88 CHRNA7 (0.53) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6410984 0.88 CHRNA7 (0.53) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6415382 0.88 CHRNA7 (0.58) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6415025 0.88 CHRNA7 (0.53) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6415375 0.88 CHRNA7 (0.58) CHRNA7NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL6415869 0.85 CHRNA7 (0.58) CHRNA7KDM4EALDH1A1HPGD
SCHEMBL6413499 0.85 CHRNA7 (0.58) CHRNA7KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC 2005-09-29 US claimed
EP-1476449-A1 FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-11-17 EP claimed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
WO-2003070732-A1 FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO claimed
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC 2005-09-29 US disclosed
US-6858613-B2 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC. (US) 2005-02-22 US disclosed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease NAT1, CYP11B1, COASY CHRNA7 1475/4885NPC1 142/4885RAB9A 2031/4885
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease CHRNA7, UGT2B7, CHRNA5 CHRNA7 1/4885NPC1 221/4885RAB9A 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.